Acadia Pharmaceuticals (ACAD) Cash from Investing Activities Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Acadia Pharmaceuticals | 3.69 Bn | 2.84 Bn | 243.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.51% |
| Dec 31, 2025 | 13.74% |
| Sep 30, 2025 | -20.29% |
| Jun 30, 2025 | -18.55% |
| Mar 31, 2025 | -43.99% |
| Dec 31, 2024 | 20.91% |
| Sep 30, 2024 | -59.46% |
| Jun 30, 2024 | -48.77% |
| Mar 31, 2024 | -21.22% |
| Dec 31, 2023 | 71.63% |
| Sep 30, 2023 | 1.42% |
| Jun 30, 2023 | -118.04% |
| Mar 31, 2023 | 16.52% |
| Dec 31, 2022 | 0.38% |
| Sep 30, 2022 | -4.40% |
| Jun 30, 2022 | -28.16% |
| Mar 31, 2022 | 19.93% |
| Dec 31, 2021 | 0.69% |
| Sep 30, 2021 | -0.18% |
| Jun 30, 2021 | -18.19% |
| Mar 31, 2021 | 16.90% |
| Dec 31, 2020 | -32.36% |
| Sep 30, 2020 | 79.08% |
| Jun 30, 2020 | 23.55% |
| Mar 31, 2020 | -5.10% |
| Dec 31, 2019 | -48.28% |
| Sep 30, 2019 | -23.90% |
| Jun 30, 2019 | 16.62% |
| Mar 31, 2019 | 17.39% |
| Dec 31, 2018 | -85.23% |
| Sep 30, 2018 | 58.68% |
| Jun 30, 2018 | 47.48% |
| Mar 31, 2018 | 36.33% |
| Dec 31, 2017 | 12.39% |
| Sep 30, 2017 | 55.34% |
| Jun 30, 2017 | 35.47% |
| Mar 31, 2017 | 68.67% |
| Dec 31, 2016 | 78.50% |
| Sep 30, 2016 | -105.44% |
| Jun 30, 2016 | -25.89% |
| Mar 31, 2016 | -80.79% |
| Dec 31, 2015 | 56.24% |
| Sep 30, 2015 | 23.07% |